{
  "abstract": "We thank Dr Zhu for his comment1 on our article regarding the non-inferiority of pembrolizumab hybrid dosing in patients with advanced non-small cell lung cancer (NSCLC)2 and the editor for the opportunity to respond to this comment. As we welcome the discussion regarding the implications of our results, we would like to address these critiques, but we also would like to correct misconceptions concerning our results.",
  "authors": [
    {
      "affiliations": [
        "Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands"
      ],
      "name": "Michiel M Smeenk"
    },
    {
      "affiliations": [
        "Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands"
      ],
      "name": "Vincent van der Noort"
    },
    {
      "affiliations": [
        "Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands",
        "Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, Netherlands"
      ],
      "name": "Jeroen J M A Hendrikx"
    },
    {
      "affiliations": [
        "Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, ZH, Netherlands",
        "Department of Pharmacy, Haga Teaching Hospital, The Hague, Netherlands"
      ],
      "name": "Hanieh Abedian Kalkhoran"
    },
    {
      "affiliations": [
        "Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, Netherlands"
      ],
      "name": "Egbert F Smit"
    },
    {
      "affiliations": [
        "Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands"
      ],
      "name": "Willemijn S M E Theelen"
    }
  ],
  "title": "Response to: Comment on ’Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ by Zhu",
  "uid": "b9549b17-9f18-576b-9dcf-95bb6de55e9f"
}